CD4 and COVID-19: SARS-CoV-2 spike glycoprotein (S)-reactive CD4+ cells were detected in 83% of patients with COVID-19 [32], as well as in 35% of healthy subjects demonstrating the presence of S-cross-reactive T cells, probably generated during previous infections with endemic coronaviruses.